• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

强迫症药物无反应的临床预测因素

Clinical predictors of drug nonresponse in obsessive-compulsive disorder.

作者信息

Shetti Chandrashekhar N, Reddy Y C Janardhan, Kandavel Thennarasu, Kashyap Kartik, Singisetti Srinivas, Hiremath Avinash S, Siddequehusen Mulia Umar-Faruq, Raghunandanan Samar

机构信息

Department of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 560029, India.

出版信息

J Clin Psychiatry. 2005 Dec;66(12):1517-23. doi: 10.4088/jcp.v66n1204.

DOI:10.4088/jcp.v66n1204
PMID:16401151
Abstract

OBJECTIVE

Obsessive-compulsive disorder (OCD) is often a chronic and disabling illness with high comorbidity. Serotonin reuptake inhibitors (SRIs) are effective in treating OCD. However, 40% to 60% of patients with OCD do not respond adequately to SRIs. This study aims to identify the clinical predictors of nonresponse to SRIs in OCD by comparing SRI responders and nonresponders.

METHOD

122 subjects with a diagnosis of DSM-IV OCD of at least 1 year's duration and with treatment history of adequate trials with at least 2 SRIs were recruited from December 2002 to March 2004. Of these, 67 were SRI responders and 55 were SRI nonresponders; they were compared on various clinical parameters. Nonresponse was defined as a score of >/=3 on the Clinical Global Impressions-Improvement sub-scale (CGI-I) after at least 2 adequate trials with SRIs. Response was defined as a score of 1 or 2 on the CGI-I.

RESULTS

In regression analysis, baseline severity of OCD (p = .049), comorbid major depressive disorder (p = .005), presence of sexual obsessions (p = .002), and washing (p = .008) and miscellaneous compulsions (p = .013) were identified as predictors of nonresponse to SRIs. Early age at onset showed a trend toward prediction of nonresponse (p = .056). In the univariate analysis, mixed OCD (p = .001) and poor insight (p = .023) were associated with nonresponse.

CONCLUSION

This study has identified clinical predictors of nonresponse to SRIs. These predictors may have to be taken into consideration and assessed carefully when SRIs are prescribed to treat OCD. Future studies should aim at identifying treatment modalities that are effective in SRI nonresponders.

摘要

目的

强迫症(OCD)通常是一种慢性致残性疾病,合并症发生率高。5-羟色胺再摄取抑制剂(SRIs)对治疗强迫症有效。然而,40%至60%的强迫症患者对SRIs反应不佳。本研究旨在通过比较SRIs反应者和无反应者,确定强迫症患者对SRIs无反应的临床预测因素。

方法

2002年12月至2004年3月招募了122名诊断为DSM-IV强迫症且病程至少1年、有至少2种SRIs充分试验治疗史的受试者。其中,67名是SRIs反应者,55名是SRIs无反应者;对他们的各种临床参数进行了比较。无反应定义为在至少2次充分的SRIs试验后,临床总体印象改善量表(CGI-I)得分≥3分。反应定义为CGI-I得分为1或2分。

结果

回归分析显示,强迫症的基线严重程度(p = 0.049)、合并的重度抑郁症(p = 0.005)、存在性强迫观念(p = 0.002)、洗涤(p = 0.008)和其他强迫行为(p = 0.013)被确定为对SRIs无反应的预测因素。发病年龄早显示出无反应预测的趋势(p = 0.056)。单因素分析中,混合性强迫症(p = 0.001)和自知力差(p = 0.023)与无反应相关。

结论

本研究确定了对SRIs无反应的临床预测因素。在开SRIs治疗强迫症时,可能必须考虑并仔细评估这些预测因素。未来的研究应致力于确定对SRIs无反应者有效的治疗方式。

相似文献

1
Clinical predictors of drug nonresponse in obsessive-compulsive disorder.强迫症药物无反应的临床预测因素
J Clin Psychiatry. 2005 Dec;66(12):1517-23. doi: 10.4088/jcp.v66n1204.
2
Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.西酞普兰静脉输注治疗难治性强迫症:一项开放性试验。
J Clin Psychiatry. 2002 Sep;63(9):796-801.
3
Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.阿立哌唑增效治疗难治性强迫症:一项 10 周开放性研究。
Adv Ther. 2011 Apr;28(4):341-8. doi: 10.1007/s12325-011-0011-7. Epub 2011 Mar 21.
4
Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.喹硫平增效治疗对5-羟色胺再摄取抑制剂耐药的强迫症:一项开放标签研究。
J Clin Psychiatry. 2005 Jan;66(1):73-9. doi: 10.4088/jcp.v66n0110.
5
Long-term follow-up and predictors of clinical outcome in obsessive-compulsive patients treated with serotonin reuptake inhibitors and behavioral therapy.使用5-羟色胺再摄取抑制剂和行为疗法治疗的强迫症患者的长期随访及临床结局预测因素
J Clin Psychiatry. 2001 Jul;62(7):535-40. doi: 10.4088/jcp.v62n07a06.
6
Long-term follow-up study of patients with serotonin reuptake inhibitor-nonresponsive obsessive-compulsive disorder.伴有血清素再摄取抑制剂反应不良的强迫症患者的长期随访研究。
J Clin Psychopharmacol. 2010 Jun;30(3):267-72. doi: 10.1097/JCP.0b013e3181dbfb53.
7
Dimensional predictors of response to SRI pharmacotherapy in obsessive-compulsive disorder.强迫障碍患者接受 SRI 药物治疗反应的维度预测因子。
J Affect Disord. 2010 Feb;121(1-2):175-9. doi: 10.1016/j.jad.2009.06.010. Epub 2009 Jul 3.
8
Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.利培酮增强5-羟色胺再摄取抑制剂治疗难治性强迫症的疗效。
J Clin Psychiatry. 1996 Jul;57(7):303-6.
9
A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.一项针对对5-羟色胺再摄取抑制剂难治的强迫症患者加用喹硫平的双盲、随机、安慰剂对照试验。
J Clin Psychiatry. 2004 Aug;65(8):1040-8. doi: 10.4088/jcp.v65n0803.
10
A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.一项系统评价:抗精神病药物增效治疗难治性强迫症
Mol Psychiatry. 2006 Jul;11(7):622-32. doi: 10.1038/sj.mp.4001823. Epub 2006 Apr 4.

引用本文的文献

1
Randomized trial of the efficacy of trial-based cognitive therapy for obsessive-compulsive disorder: preliminary findings.基于病例的认知疗法治疗强迫症的疗效随机试验:初步研究结果。
Trends Psychiatry Psychother. 2023;45:e20210247. doi: 10.47626/2237-6089-2021-0247. Epub 2022 May 25.
2
Executive functions and insight in OCD: a comparative study.执行功能与强迫症洞察力:一项对比研究。
BMC Psychiatry. 2021 Apr 29;21(1):216. doi: 10.1186/s12888-021-03227-w.
3
The associations of obsessive-compulsive symptom dimensions and general severity with suicidal ideation in patients with obsessive-compulsive disorder: The role of specific stress responses to COVID-19.
强迫症症状维度和总体严重程度与强迫症患者自杀意念的关联:对 COVID-19 的特定应激反应的作用。
Clin Psychol Psychother. 2021 Nov;28(6):1391-1402. doi: 10.1002/cpp.2602. Epub 2021 May 5.
4
Challenges in the diagnosis and treatment of pediatric obsessive-compulsive disorder.小儿强迫症的诊断与治疗挑战
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S119-S130. doi: 10.4103/psychiatry.IndianJPsychiatry_524_18.
5
Course and outcome of obsessive-compulsive disorder.强迫症的病程及转归
Indian J Psychiatry. 2019 Jan;61(Suppl 1):S43-S50. doi: 10.4103/psychiatry.IndianJPsychiatry_521_18.
6
Pharmacotherapy for Hoarding Disorder: How did the Picture Change since its Excision from OCD?囤积障碍的药物治疗:从强迫症中切除后,情况有何变化?
Curr Neuropharmacol. 2019;17(8):808-815. doi: 10.2174/1570159X17666190124153048.
7
Are Mentalizing Abilities and Insight Related to the Severity of Obsessive-Compulsive Disorder.心理化能力和洞察力与强迫症的严重程度有关吗?
Psychiatry Investig. 2018 Sep;15(9):843-851. doi: 10.30773/pi.2018.05.02.2. Epub 2018 Aug 20.
8
Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).精神药理学治疗强迫症(OCD)。
Curr Neuropharmacol. 2019;17(8):710-736. doi: 10.2174/1570159X16666180813155017.
9
A comparative study of quality of life and disability among schizophrenia and obsessive-compulsive disorder patients in remission.缓解期精神分裂症患者与强迫症患者生活质量及残疾状况的对比研究。
Ind Psychiatry J. 2016 Jul-Dec;25(2):210-215. doi: 10.4103/ipj.ipj_94_15.
10
Cognitive behavioral therapy in pharmacoresistant obsessive-compulsive disorder.药物难治性强迫症的认知行为疗法
Neuropsychiatr Dis Treat. 2016 Mar 14;12:625-39. doi: 10.2147/NDT.S101721. eCollection 2016.